Meeting
2022 ASCO Annual Meeting
An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
Presenter
Atul Sharma, MD
All India Institute of Medical Sciences
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
CTRI/2018/03/012422
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6004)
DOI
10.1200/JCO.2022.40.16_suppl.6004
Abstract #
6004
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
Speaker: Vijay Maruti Patil, MD, MBBS
Videos & Slides
2018 ASCO Annual Meeting
Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
Speaker: Vijay Maruti Patil, MD, MBBS
Videos & Slides
2017 ASCO Annual Meeting
Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study.
Speaker: Pierce K. H. Chow, MBBS FRCS, PhD
Speaker: Mehmet Asim Bilen, MD